Press Releases - Daiichi Sankyo US
News, Events, Updates, Breakthroughs. Journalists may direct questions to [email protected]. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team. Press announcements are archived by …
News Room - Daiichi Sankyo US
Industry Veteran, Dr. Mark Rutstein, Joins Daiichi Sankyo to Lead Global Oncology Clinical Development Program Read More Daiichi Sankyo, Inc. has taken measures to contribute to the overall effort to limit the spread of the virus that causes COVID-19.
Media - Daiichi Sankyo
Feb 19, 2024 · Tokyo and Basking Ridge, NJ – (February 19, 2024) – Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the U.S. for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC ...
Passion for innovation. Compassion for patients. - Daiichi Sankyo US
For people affected by cancer, Daiichi Sankyo turns hope into possibility. Possibility into reality. Our collective craft is medicine. We’re transforming how cancer and other disease are treated. More than 120 year of heritage inspires us to meet new challenges.
Press Releases - Daiichi Sankyo US
Sep 13, 2024 · DESTINY-Breast12 is an open-label, multicenter, phase 3b/4 clinical trial designed to evaluate the efficacy and safety of ENHERTU (5.4 mg/kg) in patients with previously treated advanced/metastatic HER2 positive breast cancer.
Daiichi Sankyo and Merck Announce Global Development and ...
Oct 19, 2023 · Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and commercialization agreement for three of Daiichi Sankyo’s DXd antibody drug conjugate (ADC) candidates: patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I …
Media - Daiichi Sankyo
Oct 24, 2022 · Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone. Tokyo and Basking Ridge, NJ – (October 24, 2022) – Daiichi Sankyo (TSE: 4568) received notification of acceptance by the U.S. Food and Drug Administration (FDA) of the New Drug Application ...
Media - Daiichi Sankyo
Jul 20, 2023 · The FDA concurrently approved a companion diagnostic test to detect FLT3 -ITD mutations in patients with newly diagnosed AML. Daiichi Sankyo is committed to ensuring that patients in the U.S. who are prescribed VANFLYTA can access the medication and receive appropriate financial support.
Media - Daiichi Sankyo
Dec 23, 2021 · Designed using Daiichi Sankyo’s proprietary DXd ADC technology, patritumab deruxtecan is comprised of a fully human anti-HER3 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload (an exatecan derivative, DXd) via a stable tetrapeptide-based cleavable linker.
Daiichi Sankyo Highlights Progress in Creating New Standards of …
May 21, 2024 · Data at ASCO showcasing the company’s progress in creating new standards of care for patients with cancer will include the late-breaking positive results of the DESTINY-Breast06 phase 3 trial (LBA #1000) evaluating ENHERTU ® (trastuzumab deruxtecan) compared to standard of care chemotherapy in patients with HR positive, HER2 low (IHC 1+ or ...